Success Story: Illuminating Alzheimer’s and Related Cognitive Disorders: NIW Approved After RFE for a Pakistani Postdoctoral Fellow
Client’s Testimonial:
"Thank you very much for your hard work and dedicated support throughout this process. It was a three-prong RFE with extensive additional evidence requested, but your team prepared such a strong and well-structured response that the officer was fully convinced...Thank you again for your outstanding assistance.”
On February 24th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the field of Neuroscience (Approval Notice).
General Field: Neuroscience
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: Pakistan
State of Residence at the Time of Filing: Illinois
Approval Notice Date: February 24th, 2026
Processing Time: 1 year, 10 months, 5 days (Premium Processing Requested)
Case Summary:
This NIW approval highlights a Pakistani neuroscience researcher whose work tackles a central challenge in brain health: understanding the molecular and physiological mechanisms that drive cognitive decline. The proposed endeavor focuses on applying electrophysiology, optogenetics, and immunoassays to Alzheimer’s disease, dementia, and related cognitive disorders to uncover disease mechanisms and identify measurable signals linked to learning and memory changes. At the time of filing, the client was continuing this work in the United States through a postdoctoral research appointment aligned with neurodegenerative disease research.
Research with National Importance
In the petition, we demonstrated substantial merit and national importance by connecting the endeavor to the rising public health and economic burden of neurodegenerative disease in an aging population. The filing emphasized that stronger mechanistic insight can support earlier detection strategies and more targeted therapeutic development in conditions where neural dysfunction remains complex and difficult to treat.
Academic Contributions and Recognition
The petition documented 15 peer-reviewed journal articles, including 5 first-authored papers, along with an abstract, a first-authored preprint, and a patent. The record also included 38 citations, showing meaningful independent reliance on the client’s findings by other researchers. In addition, the client completed at least 20 peer reviews for authoritative venues and served in editorial capacities, demonstrating repeated professional trust in the client’s technical judgment.
Recognition from Experts
The filing included expert letters explaining why the client’s research is influential beyond a single project and why continued work in the United States matters for progress in cognitive-disorder research.
One expert emphasized the importance of sustaining this research direction by noting:
“Losing [client]'s research due to visa issues would be a catastrophic outcome, and based on her impressive track record, it is evident that her research must be allowed to persist in the United States.”
This independent assessment reinforced the petition’s showing that the client is well-positioned to continue advancing the proposed endeavor and that the work has recognized value to the broader research community.NIW Approval and Outlook
The I-140 NIW petition was filed on April 19th, 2024. An RFE was issued on December 8th, 2025, and the case was approved on February 24th, 2026, following an upgrade to premium processing. In the filing and RFE response, we presented a clear NIW framework showing that the endeavor has substantial merit and national importance, that the client is well-positioned through a documented record of publications, citations, and trusted peer-review activity, and that granting the waiver benefits the United States by supporting continued progress in research on Alzheimer’s disease and related cognitive disorders.